230 related articles for article (PubMed ID: 25130523)
1. A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera.
Lussana F; Carobbio A; Randi ML; Elena C; Rumi E; Finazzi G; Bertozzi I; Pieri L; Ruggeri M; Palandri F; Polverelli N; Elli E; Tieghi A; Iurlo A; Ruella M; Cazzola M; Rambaldi A; Vannucchi AM; Barbui T
Br J Haematol; 2014 Nov; 167(4):541-6. PubMed ID: 25130523
[TBL] [Abstract][Full Text] [Related]
2. Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients.
Barbui T; Thiele J; Carobbio A; Guglielmelli P; Rambaldi A; Vannucchi AM; Tefferi A
Am J Hematol; 2014 Jun; 89(6):588-90. PubMed ID: 24535932
[TBL] [Abstract][Full Text] [Related]
3. Masked polycythemia vera diagnosed according to WHO and BCSH classification.
Barbui T; Thiele J; Carobbio A; Gisslinger H; Finazzi G; Rumi E; Luigia Randi M; Vannucchi AM; Gisslinger B; Müllauer L; Ruggeri M; Rambaldi A; Tefferi A
Am J Hematol; 2014 Feb; 89(2):199-202. PubMed ID: 24166817
[TBL] [Abstract][Full Text] [Related]
4. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
5. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
[TBL] [Abstract][Full Text] [Related]
6. Masked polycythaemia vera: presenting features, response to treatment and clinical outcomes.
Alvarez-Larrán A; Angona A; Ancochea A; García-Pallarols F; Fernández C; Longarón R; Bellosillo B; Besses C
Eur J Haematol; 2016 Jan; 96(1):83-9. PubMed ID: 25810304
[TBL] [Abstract][Full Text] [Related]
7. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
Tefferi A
Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
[TBL] [Abstract][Full Text] [Related]
8. Masked polycythemia vera (mPV): results of an international study.
Barbui T; Thiele J; Gisslinger H; Finazzi G; Carobbio A; Rumi E; Luigia Randi M; Bertozzi I; Vannucchi AM; Pieri L; Carrai V; Gisslinger B; Müllauer L; Ruggeri M; Rambaldi A; Tefferi A
Am J Hematol; 2014 Jan; 89(1):52-4. PubMed ID: 23996471
[TBL] [Abstract][Full Text] [Related]
9. The role of serum erythropoietin level and JAK2 V617F allele burden in the diagnosis of polycythaemia vera.
Ancochea A; Alvarez-Larrán A; Morales-Indiano C; García-Pallarols F; Martínez-Avilés L; Angona A; Senín A; Bellosillo B; Besses C
Br J Haematol; 2014 Nov; 167(3):411-7. PubMed ID: 25040297
[TBL] [Abstract][Full Text] [Related]
10. Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients.
Besses C; Alvarez-Larrán A; Martínez-Avilés L; Mojal S; Longarón R; Salar A; Florensa L; Serrano S; Bellosillo B
Br J Haematol; 2011 Feb; 152(4):413-9. PubMed ID: 21219298
[TBL] [Abstract][Full Text] [Related]
11. Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation.
Hexner E; Roboz G; Hoffman R; Luger S; Mascarenhas J; Carroll M; Clementi R; Bensen-Kennedy D; Moliterno A
Br J Haematol; 2014 Jan; 164(1):83-93. PubMed ID: 24903629
[TBL] [Abstract][Full Text] [Related]
12. European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia.
Kvasnicka HM; Orazi A; Thiele J; Barosi G; Bueso-Ramos CE; Vannucchi AM; Hasserjian RP; Kiladjian JJ; Gianelli U; Silver R; Mughal TI; Barbui T
Am J Hematol; 2017 Oct; 92(10):1062-1067. PubMed ID: 28685840
[TBL] [Abstract][Full Text] [Related]
13. Comparison of diagnostic criteria for polycythaemia vera.
Turkington RC; Arnold EC; Percy MJ; Ranaghan LA; Cuthbert RJ; McMullin MF
Hematology; 2007 Apr; 12(2):123-30. PubMed ID: 17454193
[TBL] [Abstract][Full Text] [Related]
14. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
15. Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status.
Finazzi G; Rambaldi A; Guerini V; Carobbo A; Barbui T
Haematologica; 2007 Jan; 92(1):135-6. PubMed ID: 17229651
[TBL] [Abstract][Full Text] [Related]
16. Uncontrolled thrombocytosis in polycythemia vera is a risk for thrombosis, regardless of JAK2(V617F) mutational status.
Ohyashiki K; Akahane D; Gotoh A; Ito Y; Tauchi T; Miyazawa K; Kimura Y; Ohyashiki JH
Leukemia; 2007 Dec; 21(12):2544-5. PubMed ID: 17611562
[No Abstract] [Full Text] [Related]
17. Thrombosis and risk factors in female patients with a rare acquired thrombophilia: chronic myeloproliferative disorder - polycythaemia vera and essential thrombocythaemia.
Pósfai É; Marton I; Kiss-László Z; Kotosz B; Széll M; Borbényi Z
Eur Rev Med Pharmacol Sci; 2014; 18(24):3810-8. PubMed ID: 25555871
[TBL] [Abstract][Full Text] [Related]
18. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance.
Wolanskyj AP; Lasho TL; Schwager SM; McClure RF; Wadleigh M; Lee SJ; Gilliland DG; Tefferi A
Br J Haematol; 2005 Oct; 131(2):208-13. PubMed ID: 16197451
[TBL] [Abstract][Full Text] [Related]
19. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
[TBL] [Abstract][Full Text] [Related]
20. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2013 Jun; 88(6):507-16. PubMed ID: 23695894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
